Drug intelligence / Profile preview

E1M184V peptide vaccine

Development stage: Phase 1
Lead developer: NIH Clinical Center
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intramuscular

Overview

E1M184V is a therapeutic peptide vaccine developed as an immunostimulant for the treatment of HIV infection. It is designed to stimulate the immune system to recognize and respond to HIV antigens, potentially impeding the development of antiretroviral resistance. The vaccine has also been investigated for use in precancerous conditions. Its mechanism involves enhancing immune responses through immunostimulation, and it has been studied in combination with adjuvants such as incomplete Freund's adjuvant and GM-CSF to further boost immunogenicity. The primary developer is the National Institutes of Health Clinical Center[1].

Targets

HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)

Beyond the preview

Go deeper on E1M184V peptide vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on E1M184V peptide vaccine.

Explore the full profile